15.07.2024 07:28:39 - dpa-AFX: EQS-News: CompuGroup Medical SE & Co. KGaA publishes half-year figures for the financial year 2024 (english)

CompuGroup Medical SE & Co. KGaA publishes half-year figures for the
financial year 2024

EQS-News: CompuGroup Medical SE & Co. KGaA / Key word(s): Half Year Results
CompuGroup Medical SE & Co. KGaA publishes half-year figures for the
financial year 2024

15.07.2024 / 07:28 CET/CEST
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

CompuGroup Medical SE & Co. KGaA publishes half-year figures for the
financial year 2024

Against the backdrop of the ad-hoc announcement on July 9, 2024, the general
partner of CompuGroup Medical SE & Co. KGaA (ISIN: DE000A288904 | WKN:
A28890) ("CGM") has decided to prepone the publication of the financial
results for the first half of the financial year 2024.

The financial results for the first half of the financial year are as
follows:

  * Group revenues decreased by 6% year-on-year to EUR 562 million (prior
    year period: EUR 595 million), mainly due to TI one-time effects in the
    prior year


  * Organic revenues decreased by 5% year-on-year (prior year period +12%),
    adjusted for prior-year TI one-time effects +1% year-on-year


  * Recurring revenues grew by 6% year-on-year to EUR 423 million (prior
    year period EUR 401 million)


* Recurring revenue share at 75% (prior year period 67%)

  * Adjusted EBITDA declined by 14% year-on-year to EUR 114 million (prior
    year period: EUR 133 million)


  * Adjusted earnings per share (EPS) are down to EUR 0.81 (prior year
    period: EUR 1.07)


  * Free cash flow amounted to EUR 39 million (prior year period: EUR 83
    million)


  * Net debt increased from EUR 703 million by the end of 2023 to EUR 779
    million by the end of June 2024


  * Leverage has increased from 2.8x by the end of 2023 to 3.3x by the end
    of June 2024


In the Ambulatory Information Systems (AIS) segment (since 2024 including
the former CHS segment) revenues in the first six months of 2024 decreased
by 10% year-on-year to EUR 338 million, mainly due to one-time effects
related to the Telematics Infrastructure hardware connector exchange and
software upgrade in the first half of the prior year. Organically and
excluding the TI one-time effects, revenues were on the prior year level.
Recurring revenues grew by 4%, increasing the recurring share by 10
percentage points to 77%.

Revenues in the Hospital Information Systems (HIS) segment increased in the
first six months of 2024 by 4% to EUR 156 million. Adjusted for acquisitions
and FX effects, organic growth was 4%, mainly attributable to increased
revenues in Austria, Spain and from projects related to the Hospital Future
Act. Recurring revenues increased to EUR 113 million, corresponding to 73%
of total revenues.

In the Pharmacy Information Systems (PCS) segment revenues declined in the
first six months of 2024 by 1 % to EUR 68 million, in particular due to
strong non-recurring sales in prior year period. Organically, revenues
declined by 1%. Recurring revenues in the PCS segment increased by 6% to EUR
49 million compared to the same period of the prior year.

In all three segments investments into the future of e-health were made
including Artificial Intelligence, data-based and patient-centered
solutions. R&D expenses for the group amounted to EUR 125 million in the
first six months of 2024 (prior year period: EUR 120 million).

On July 9, CGM revised its guidance for the financial year 2024 for organic
revenue growth and adjusted EBITDA. The half-year interim report published
today contains the full revised guidance for the financial year 2024. The
revised guidance is as follows (compared to the original guidance published
on February 7, 2024):

Group

Organic revenue development (adjusted for acquisitions and currency effects)
is now expected in a range between -2% and 0% year-on-year (previously 4 %
and 6 %). The share of recurring revenues as of total revenues is expected
unchanged between 65 % and 70 %. Adjusted EBITDA is now expected in a range
between EUR 220 million and EUR 250 million (previously EUR 270 million and
EUR 310 million). Adjusted earnings per share (diluted) are now expected in
a range between EUR 1.55% and EUR 1.95% (previously: increase of
approximately 10 % compared to the prior year). Free cash flow is now
expected in a range between EUR 40 million and EUR 60 million (previously
EUR 70 million and EUR 100 million).

Segments

For the AIS segment CGM now expects an organic revenue decrease by a low to
mid single-digit percentage rate (previously growth in the low to mid-single
digit percentage range). For the HIS segment CGM now expects an organic
revenue growth by a low to mid single-digit percentage rate (previously
growth in the mid to high-single digit percentage range). For the PCS
segment CGM continues to expect an unchanged organic revenue growth in the
low to mid single-digit percentage range.

The full financial statements for the first half including explanations of
the adjustments in earnings figures year can be found in the half year
financial report at www.cgm.com/ir-publications.


---------------------------------------------------------------------------

15.07.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS
News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

---------------------------------------------------------------------------

   Language:       English
   Company:        CompuGroup Medical SE & Co. KGaA
                   Maria Trost 21
                   56070 Koblenz
                   Germany
   Phone:          +49 (0)160 3630362
   Fax:            +49 (0)261 8000 3200
   E-mail:         investor@cgm.com
   Internet:       www.cgm.com
   ISIN:           DE000A288904
   WKN:            A28890
   Indices:        SDAX, TecDAX
   Listed:         Regulated Market in Frankfurt (Prime Standard);
                   Regulated Unofficial Market in Berlin, Dusseldorf,
                   Hamburg, Munich, Stuttgart, Tradegate Exchange
   EQS News ID:    1945727




End of News EQS News Service
---------------------------------------------------------------------------

1945727 15.07.2024 CET/CEST
Name WKN Börse Kurs Datum/Zeit Diff. Diff. % Geld Brief Erster Schluss
COMPUGROUP MED. NA O.N. A28890 Xetra 16,100 16.08.24 17:35:26 +0,370 +2,35% 0,000 0,000 15,750 16,100

© 2000-2024 DZ BANK AG. Bitte beachten Sie die Nutzungsbedingungen | Impressum
2024 Infront Financial Technology GmbH